SCHEMBL26880952

SCHEMBL26880952

Cc1c2c(c3sccc3c1C(C)(C)C)OC(C)(C(C)(C)C)O2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23823081 0.61 — —
SCHEMBL15473505 0.58 — —
SCHEMBL203914 0.58 DYRK1A (0.34) —
SCHEMBL20126953 0.56 ALDH1A1 (0.32) —
SCHEMBL20126955 0.56 ALDH1A1 (0.32) —
SCHEMBL24595784 0.56 HDAC3 (0.31) —
SCHEMBL18775167 0.55 MAPT (0.33) —
SCHEMBL24595789 0.55 GPR35 (0.34) —
SCHEMBL24344877 0.55 MAPT (0.40) —
SCHEMBL24344563 0.55 CYP2A6 (0.32) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365541-A1 INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-11-16 — — US disclosed
US-20230365541-A1 INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-11-16 — — US disclosed
Send feedback